| Catalog No. | HY583046 |
|---|
| Species reactivity | Human |
|---|
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
|---|
| Host species | Humanized |
|---|
| Isotype | IgG2-kappa |
|---|
| Expression system | Mammalian Cells |
|---|
| Clonality | Monoclonal |
|---|
| Target | sIL6R, Interleukin-6 receptor subunit alpha, CD126, IL-6R 1, IL-6R subunit alpha, Membrane glycoprotein 80, gp80, IL6R, IL-6RA, IL-6 receptor subunit alpha, IL-6R-alpha |
|---|
| Endotoxin level | Please contact the lab for this information. |
|---|
| Purity | >95% purity as determined by SDS-PAGE. |
|---|
| Purification | Protein A/G purified from cell culture supernatant. |
|---|
| Accession | P08887 |
|---|
| Form | Liquid |
|---|
| Storage buffer | 0.01M PBS, pH 7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
|---|
| Alternate Names | Sapelizumab, SA-237, SA237, satralizumab-mwg, 1535963-91-7 |
|---|
| Background | Tocilizumab (Anti-Human IL6R, Humanized Antibody) is an anti-human interleukin-6 receptor (IL-6R) neutralizing antibody, prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab (Anti-Human IL6R, Humanized Antibody) can be used for the treatment of rheumatoid arthritis. Tocilizumab is remarkablely effective for the study of severe COVID-19 (coronavirus disease).
• Expression of Interleukin 6 signaling receptors in carotid atherosclerosis., PMID:33350884
• Preclinical development of CD126 CAR-T cells with broad antitumor activity., PMID:33414408
• Physiological effects of modulating the interleukin-6 axis., PMID:29982781
• Increased IL-6 and Potential IL-6 trans-signalling in the airways after an allergen challenge., PMID:33471392
• IL6 receptor inhibitors: exploring the therapeutic potential across multiple diseases through drug target Mendelian randomization., PMID:39229261
• Anti-Inflammatory Effect of Muscle-Derived Interleukin-6 and Its Involvement in Lipid Metabolism., PMID:34576053
• Identification of IL-6 Signalling Components as Predictors of Severity and Outcome in COVID-19., PMID:35634332
• M1-Like Macrophages Modulate Fibrosis and Inflammation of Orbital Fibroblasts in Graves' Orbitopathy: Potential Relevance to Soluble Interleukin-6 Receptor., PMID:36617890
• The IL-6-neutralizing sIL-6R-sgp130 buffer system is disturbed in patients with type 2 diabetes., PMID:31237452
• Soluble interleukin-6 receptor-mediated innate immune response to DNA and RNA viruses., PMID:23946454
|
|---|
| Note | For research use only. Not suitable for clinical or therapeutic use. |
|---|
